Axogen Inc. (AXGN) exhibits 74.3% gross margins and -2.6% return on invested capital within Health Care (Biotechnology: Electromedical & Electrotherapeutic Apparatus), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 74.3% gross profitability converts into -3.5% operating margin and -2.6% ROIC, outpacing sector cost of capital.
ROIC: -2.6% // GM: 74.3%YoY revenue trajectory of +20.2% paired with -0.10% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +20.2% // FCF YLD: -0.10%Altman Z-Score of 18.64 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 18.64 // F-SCORE: 6/9Trading at 24.0x trailing P/E (18.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $49.37 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Electromedical & Electrotherapeutic Apparatus require continuous execution to defend -7.0% net margins.
NET MARGIN: -7.0% // D/E: 0.38x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for AXGN & activate live FRED threshold breach alerts.